logo     Print Page | Close Window


BPMC (Common Stock) $79.24 Stock is Up 0.91 (1.16%)
04/26/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15
minutes delay
Refresh quote

Corporate Profile

Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company’s approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases.Read More

Upcoming Events

Q1 2018 Blueprint Medicines Corp Earnings Conference Call
Wednesday, May 2, 2018 8:30 a.m. ET

View More


Blueprint Medicines – Investor Presentation (January 2018)